Oculus Innovative Sciences (OCLS) : Traders are bullish on Oculus Innovative Sciences (OCLS) as it has outperformed the S&P 500 by a wide margin of 0.26% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 17.99%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 17.21% in the last 1 week, and is up 0.05% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 10.59% and the fifty day Moving Average is 16.68%. Oculus Innovative Sciences, Inc. is up 346.41% in the last three month period. Year-to-Date the stock performance stands at 273.04%.
Oculus Innovative Sciences (NASDAQ:OCLS): On Fridays trading session , Opening price of the stock was $4.45 with an intraday high of $4.48. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.14. However, the stock managed to close at $4.29, a loss of 4.45% for the day. On the previous day, the stock had closed at $4.49. The total traded volume of the day was 51,189 shares.
Oculus Innovative Sciences, Inc. is a specialty device and pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in both humans and animals. The Company offers wound care products which are sold into the human and animal healthcare markets in the United States, Mexico and Europe. The Company also operates a microbiology contract testing laboratory division that provides consulting and laboratory services to medical companies that design and manufacture biomedical devices and drugs, as well as testing of products and the Companys products. The Companys key technology, Microcyn is based on electrically charged oxychlorine small molecules designed to target a range of pathogens that cause disease. The Company completed Phase II trials for Microcyn technology.